Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

The primary endpoint of the study is the proportion of patients who achieve undetectable levels of virus at week 12 (defined as complete Early Virological Response, or cEVR). Additional endpoints include safety and tolerability as well as the proportion of patients with undetectable levels of virus at week 4 (defined as Rapid Virological Response, or RVR). Patients will be followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR. Approximately 90 patients are planned to be enrolled in this study - with approximately 30 patients receiving ANA598 and 15 receiving placebo at each dose level.

The study is being managed by the Duke Clinical Research Institute (DCRI) under the leadership of John McHutchison, M.D. and is being conducted at a number of clinical sites in the United States. An independent DMC is responsible for reviewing the safety data in the trial and has endorsed escalating to the second dose level of 400 mg bid. This cohort is now open for enrollment and Anadys expects to initiate dosing in January 2010.

About ANA598

ANA598 is a non-nucleoside inhibitor of the HCV RNA polymerase and is wholly owned by Anadys. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability. In a monotherapy study in treatment-naïve genotype 1 patients, treatment with ANA598 for three days led to median end-of-treatment declines in viral load ranging from 2.4 to 2.9 log10 in three separate dose groups. No patient at any dose level showed evidence of viral rebound while on ANA598, and there were no serious adverse events. Those patients from the monotherapy study who subsequently received pegylated interferon and ribavirin all exhibited further viral load decline, demonstrating that viral variants revealed by brief treatment with A
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Today the U.S. Food ... Bexsero® for the prevention of serogroup B meningococcal ... and Pfizer,s vaccine Trumenba®, which received FDA approval in ... this devastating disease. "I have heard ...
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Cord Blood America, Inc . ( http://www.cordblood-america.com ) (OTC ... stem cell preservation company focused on bringing the ... internationally, announced today a Special Meeting of its shareholders on ... reverse stock split of one share for each 500 outstanding ...
... Calif., Feb. 10, 2011 PRO-DEX, INC. (Nasdaq: ... quarter and six months ended December 31, 2010. ... 8% to $6.2 million from $5.7 million for the corresponding ... the Company,s medical device products to its largest customer, and ...
Cached Medicine Technology:Cord Blood America Announces Special Shareholder Meeting 2Cord Blood America Announces Special Shareholder Meeting 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 2Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 4Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 5Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 6Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 7
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... TripAdvisor as the number one best large hotel for families ... world for their annual Travelers’ Choice Awards. , TripAdvisor ... website is home to millions of unbiased and honest traveler ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many ... it on Facebook, Twitter, and Pinterest. The fans will have ... a lottery every week. , Moreover, the company has extended ... Angelweddingdress homepage for more information. , Angelweddingdress ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... health, social skills in the process, experts say , FRIDAY, ... mean days spent at the beach or lake, afternoon bike ... is more likely to be lived in the not-so-great indoors, ... "human" contact. , The indoor child phenomenon concerns health experts ...
... A twice weekly hip strengthening regimen performed for six ... some cases eliminating -- knee pain referred to as ... study by Tracy Dierks, assistant professor in the Department ... based on the theory that stronger hips would correct ...
... ... better ROI , ... Rochester, NY and Piscataway NJ (PRWEB) June 4, 2010 -- UniteU Technologies, Inc., a ... optimizing solutions for online stores, are announcing the availability of Filtered Navigation Search Express ...
... Theurer Cancer Center at Hackensack University Medical Center announced ... the American Society of Clinical Oncology (ASCO) annual meeting ... Research highlights include a comparison of first-line treatments for ... of a new genetically engineered cancer therapy, and the ...
... Blood Institute (NHLBI) has stopped a clinical trial evaluating a ... children with sickle cell anemia and iron overload because of ... than the existing treatment. The 26-site trial, Stroke ... between the ages of 5 and 18 who had already ...
... role in the aging process appears to play a role ... according to researchers from the Center for Stem Cell Biology ... Jefferson University. In the study, published online in ... protein interaction that controls the silencing of Oct4, a key ...
Cached Medicine News:Health News:Move Childhood Back Outdoors This Summer 2Health News:Move Childhood Back Outdoors This Summer 3Health News:Hip exercises found effective at reducing, eliminating common knee pain in runners 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 2Health News:UniteU and Celebros Launch Dynamic Cross-Sell and New Version of Filtered Navigation Search 3Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 2Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 3Health News:John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting 4Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 2Health News:Stroke prevention study in children with sickle cell anemia, iron overload stopped early 3Health News:Gene related to aging plays role in stem cell differentiation 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: